Spectral Medical (TSE:EDT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Spectral Medical Inc. has announced a significant milestone in their Tigris trial, achieving a record-breaking enrollment of 116 patients as of June 2024. This surge includes the highest monthly enrollment to date, bringing the trial closer to its completion with only 34 more participants required. The company is advancing PMX, a potential septic shock treatment device, with the aim of obtaining U.S. FDA approval.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.